August 23

PLEASANTON, California, August 23, 2011 - - cobas BRAF Mutation Test is used to identify patients with melanoma tumors that harbor a genetic mutation which can be treated with Zelboraf (vemurafenib) Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas BRAF Mutation Test is now commercially available in Europe and in countries that recognize the CE mark.

LOS ANGELES, August 23, 2011 - Futurestep, a Korn/Ferry Company (NYSE: KFY) specializing in high impact talent solutions, today announced that it was named by HRO Today Magazine as one of the leading RPO providers in its 2011 industry Baker's Dozen listing and clinching the coveted top placing in the 'Breadth of Service' category.

NAGOYA, Japan, August 23, 2011 - - Menicon Expanding Its Presence in Custom Contact Lens Market - Menicon Company Ltd.

OSLO, Norway, August 23, 2011 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S.

UPPSALA, Sweden, August 23, 2011 - HighCapacity Instruments,Combining AllergyandAutoimmunity Testing BasedonProvenPhadiaTechnologyforReliability Today Phadia, the global leader in allergy and autoimmune related diseases diagnostics, announced the launch of Phadia's new allergy and autoimmunity testing instruments; Phadia 2500 and Phadia 5000.
Older News
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
Copyright© 2011 The Gaea Times